Success for Testbiotech: Merck patent revoked

Patent covered usage of human oocyts

Tuesday, 21 April 2015

Testbiotech has won an opposition against a patent held by Merck Serono at the European Patent Office (EPO). Patent EP 1794287 covered a process for the production and use of human oocytes (egg cells). European patent law excludes patents on the human body at the various stages of its development, including so-called germ cells. Testbiotech filed the opposition in April 2010 and the patent finally was revoked end of March 2015.

Does glyphosate cause cancer?

Important gap in German risk assessment

15 April 2015 / Research carried out by the Pesticide Action Network (PAN Germany) has identified an important gap in the risk assessment of glyphosate carried out by the German Federal Institute for Risk Assessment (BfR). There are already several scientific publications showing that glyphosate can cause oxidative stress to cells, which is a possible cause of cancer. Nevertheless, the BfR did not take this into account in their risk assessment.

New publication shows unexpected reactions in genetically engineered maize MON810 when exposed to environmental stress

Gene expression and content of insecticidal toxins cannot be reliably predicted

Friday, 10 April 2015

Scientists from Switzerland and Norway have now published the results of an investigation into genetically engineered maize MON810, which produces an insecticidal protein, a so-called Bt toxin (Trtikova et al., 2015). In the investigation, two varieties of maize MON810 were grown in climate chambers and subjected to defined stress conditions i.e. cold/wet and hot/dry. According to the authors, this is the first study to report on whether there is a relationship between transgene expression and protein production in Bt maize under changing environmental conditions.


Subscribe to testbiotech RSS